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Abstract
Multiple myeloma is an incurable cancer with expansion of malignant plasma cells
in the bone marrow. Previous studies have shown that monocytes and
macrophages in the bone marrow milieu are important for tumor growth and
may play a role in the drug response. We therefore characterized monocytes in
bone marrow aspirates by flow cytometry. We found that there was significant
correlation between the proportion of CX3CR1
þ, CD16þCD14dim non classical
monocytes, and percent plasma cells (PC) in the bone marrow of myeloma
patients. The bone marrow monocytes could be stimulated by TLR ligands to
produce cytokines which promote myeloma cell growth. The proportion of the
non-classical monocytes increased with the tumor load, particularly in patients
with tumor loads in the range of 10–30% bone marrow PC.
Introduction
Multiplemyeloma is amalignancy of plasma cells (PC), usually
located to the bone marrow. Survival and proliferation of
myeloma cells is critically dependent on the bone marrow
microenvironment [1]. Stromal cells includingmonocytes and
macrophages can produce inflammatory cytokines such as IL6,
which promote growth and increase survival of myeloma
cells [2, 3]. In addition, macrophages and monocytes may
produce anti-inflammatory cytokines that can promote tumor
growth indirectly [3, 4]. In vitro, it has been shown that
macrophages could support growth of myeloma cells and
rescue them from chemotherapeutic drugs [5].
The bone marrow microenvironment is modified by the
presence of malignant PCs. Thus, increased differentiation of
monocytes into bone resorbing osteoclasts characterizes multi-
ple myeloma [6]. Furthermore, malignant PCs may modulate
the numbers and composition of immune cells in the bone
marrow.Monocytes andmacrophages are central in inflamma-
tory responses, and more macrophage/monocytes have been
found in the bonemarrow of myeloma patients compared with
normal controls [7, 8]. It is however, not knownwhich sub-types
of monocytes are associated with myeloma disease.
Humanbloodmonocytes can be classified into three distinct
populations, classical CD16CD14þ monocytes, intermediate
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CD16þ CD14þ and non-classical CD16þCD14dim monocytes.
The classical and intermediate monocytes are similar to the
CCR2þ inflammatory mouse monocytes [9, 10]. In contrast,
the CD16þCD14dim cells are similar to CX3CR1
þ mouse
monocytes, which patrol blood vessels and respond to viral
RNA and double-stranded DNA by producing granulocyte
attracting mediators [11]. Such cells have been associated with
inflammatory disease such as rheumatoid arthritis and
systemic lupus erythematosus (SLE) [11, 12].
Here, we set out to characterize the monocyte sub-types in
the bonemarrow of a cohort ofNorwegianmyeloma patients.
Results
CD16þCD14dim monocytes increase in the bone
marrow of myeloma patients
In order to determine the sub type of monocytes present in
myeloma patients, bone marrow cells from patients suffering
from multiple myeloma were stained with a panel of
antibodies against different monocyte subpopulations and
analyzed by flow cytometry. The gating strategy is shown in
Figure 1A. Gates were set on live cells with forward and side
scatter (i), and on cells also expressing CD45 (ii). Lineageþ
(CD3, CD19, CD138, CD56, CD15, CD34, and CD235a) and
CD66bþ granulocytes were then gated out from the CD45þ
cells (iii). The HLA DR profile within this gate is shown (iv).
Plots of CD14 and CD16 expressing populations of the
gated HLADRþ cells is shown in Figure 1B on cells from
representative patients. The quantity of monocyte types was
determined as a ratio of CD16þCD14dim/CD14high cells
(Fig. 1C) and as percentage CD16þCD14dim cells of total
CD45þ cells (Fig. 1D), respectively. The ratios of
CD16þCD14dim/CD14high cells increased with percent bone
marrow PC, suggesting that more non-classical monocytes
were present in bone marrow as the tumor mass increased
(Fig. 1C). Similarly, the fraction of CD45þ cells that were
CD16þCD14dim was significantly higher in bone marrow
from patients with 10–30% bone marrow plasma cells
compared to patients with lower numbers of bone marrow
plasma cells [Fig. 1D(i)]. Interestingly, patients with more
than 30% plasma cells had variable amounts of
CD16þCD14dim cells, ranging from very low to high
(Fig. 1D). No significant changes in the corresponding
CD14high population was observed [Fig. 1D(ii)].The propor-
tion of non classical/classical bone marrow monocytes found
inpatientswith lowpercent PCand theirmarkerswere similar
to what was found in healthy controls (mean proportion: low
percent PC: 0.0562þ/0.0011 and healthy controls:
0.08) [13]. The bone marrow CD16þCD14dim cells were
similar to mouse patrolling monocytes as they expressed high
levels of CX3CR1 and lower levels of CD163, CCR2, and
CD62L than their CD14high counterpart (Fig. 1E). We also
found that high proportions of CD16þCD14dim monocytes
were present in the bone marrow and blood of the patients
(Fig. S4), indicating that these cells circulate.
The frequency of CD16þCD14dim monocytes
increases in patients with high amounts of
apoptotic myeloma cells.
The expansion of the non-classical monocytes could be
generated by several mechanisms. One explanation could be
that the non-classical monocytes were expanded after
stimulation with M-component produced by the myeloma
cells. Immunoglobulins in the formof immune complexes have
been associated with inflammatory diseases. In SLE for
example, patients have high numbers of non-classical mono-
cytes concomitant with elevated levels autoantibodies and
immune complexes [11]. As myeloma cells produce high
quantities of immunoglobulins [10], we asked whether there
was a correlation between the concentration of M-component
in serum and proportion of CD16þCD14dim cells in the bone
marrow. A weak correlation was found (Fig. 2A, B).
Furthermore, when the patients were divided into two groups,
one group with M-component above the median level of all
patients (i.e., 25 g/L), and one group below we also observed
that patients withM-component above 25 g/L had significantly
moreCD16þCD14dimmonocytes (Fig. 2A, B) than the patients
with low M-component. However, the M component levels
and may only reflect tumor loads in the patients.
There could also be other mechanisms behind the increase
of the non-classical monocytes in themyeloma bonemarrow.
It is proposed that sterile inflammation is one of the
mechanisms behind symptoms of multiple myeloma [2], but
the driving forces behind the inflammation are not known.
However, it has been proposed that dying cancer cells could
cause inflammation [2]. Indeed, macrophage activation and
sterile inflammation was seen in mice where DNA from
apoptotic cells accumulated in macrophages [14]. We
therefore set out to investigate whether there was increased
apoptosis of myeloma cells in the patients with elevated levels
CD16þCD14dim cells. In some patients, sufficient cells were
available for staining with markers for cell death, and we
detected significantly more apoptotic PC in patients with
intermediate tumor load than in patients with less than 10 or
more than 30% myeloma cells (Fig. 2C). We also found that
the proportion of non classical monocytes increased with the
proportion of apoptotic myeloma cells (Fig. S1).
Bone marrow monocytes stimulated with TLR
ligands produce myeloma growth factors
As we found that there were more apoptotic myeloma cells in
the patients with high levels of non-classical monocytes, we
hypothesized that this expansion could be a result of an
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Figure 1. CD16þCD14dim monocytes increase in the bone marrow of myeloma patients. (A) Gating strategy: Cells were stained with a cocktail of
antibodies against CD66b, lineage (CD3, CD19, CD56, CD138, CD15, CD34, and CD235a), CD45, HLADR, CD16, and CD14 and analyzed on an LSR II
Flow cytometer. Gates were set on FSC and SSC (i), doublets were excluded, and gates were set on the CD45þcells (ii). Lineage andCD66bþwere further
excluded (iii). HLA DRþ cells are shown in (iv), and CD14 and CD16 proﬁles as shown in (B) were analyzed on these cells. (B) Representative CD14 and
CD16 proﬁles from bone marrow aspirate from two patients with 30 and 2% PC, respectively. The gates indicated show the populations of %
CD16þCD14dim and CD14high cells, respectively. (C) Correlation between the ratio of CD16þCD14dim cells/CD14high cells and percent PC in the bone
marrowof patients (n¼ 33). Each dot represents a value from a patient as estimated by the gating indicated in Figure 1B. The P-valuewas calculated from
Spearman’s test. (D) CD16þCD14dimmonocytes increase in the bonemarrow of patients with intermediate levels of 10–30%plasma cells. Bonemarrow
monocytes were stained and analyzed as described above and inMethods. Figures showmonocyte populations as percent of CD45þ cells. Patients were
grouped as low percent PC (0–10%) (n¼ 9), intermediate (10–30%) (n¼ 12), and high (>30%) (n¼ 12). Each dot represents a patient. Monocyte
populations: (i) CD16þCD14dim, (ii) CD14high, and (iii) all monocyte populations (lineagegranulocyte CD14þ). Statistical analysis was performed with
Mann–Whitney Test. (E) CD16þCD14dim cells express markers deﬁning the CX3CR1 subpopulation of monocytes. Representative histograms of CX3CR1,
CCR2, CD163, and CD62L expression on gated CD16þCD14dim and CD14high monocytes. Gates were set as described in (A). FMO (ﬂuorescence minus
one) is used as negative control.
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inflammatory response generated by nucleic acids released
from dying myeloma cells. The non-classical monocytes had
the potential to respond to nucleic acids since we as well as
others [15], detected toll-like receptor (TLR) 8 expression on
these cells (data not shown).We also set out to test whether the
non-classical monocytes could be stimulated to produce
inflammatory cytokines by TLR8 agonists. As insufficient bone
marrow aspirate was available to sort and stimulate the two
different monocyte populations separately, we relied on the
observations that the twopopulations respond todifferentTLR
ligands [15]. Indeed, as reported by Cros et al., we confirmed
that only non-classical bloodmonocytes responded to the base
analogue TLR8 ligand CL075 and not to LPS [11], whilst, the
classical CD14high blood monocytes only responded to the
TLR4 ligand LPS and not the TLR8 ligand (Fig. 3A).
Stimulation of the monocytes enriched from the bonemarrow
ofmyeloma patientswith the TLR8 ligandCL075 inducedTNF
a production (Fig. 3B). Indeed, we found that non classical
monocytes produced growth factors that could support
myeloma cells (Fig. S3b).Taken together, the data shown in
Figure 2A and B indicates that the non-classical monocytes
from the patients bone marrow have the potential to be
stimulated by nucleic acids. Other inflammatory cytokines
known to support myeloma growth, such IL6 and CCL3
(Fig. 2C) were also secreted into the supernatant after
stimulation of the bone marrow monocytes with the TLR8
agonist. The classical monocytes could also produce inflam-
matory cytokines since LPS treatment of enriched bone
Figure 2. The frequency of CD16þCD14dimmonocytes increaseswithM-component and at high frequencies of apoptoticmyeloma cells. (A) Increase in
CD16þCD14dim monocytes correlates with concentration of M component in serum. This ﬁgure shows the concentration of M-component in the
patients’ serum versus the ratio of CD16þCD14dim/CD14high cells. Each dot represents a patient (n¼ 22). P-value was calculated from a Spearman’s test.
(B) The proportions of CD16þCD14dimmonocytes were signiﬁcantly higher in patients with high levels ofM-component. Patients were grouped into two
groups, belowmedian value of 25 g/L (0–25g/L, n¼ 12) and above (>25g/L, n¼ 10), serumM-component. Each dot represents one patient and P-value
was calculated fromMann–Whitney Test. (C) Patients with intermediate levels of bonemarrow PCs hadmore apoptotic PCs. Bone marrow aspirate cells
were stainedwith a cocktail of anti CD138, CD38, CD19, CD3, CD45, Annexin V, and 7AAD.Gateswere set on live cells; duplet and lineage (CD3, CD19)
were excluded. Gates were then set on the CD138þ CD38þ myeloma cells and the frequency of Annexin Vþ 7AADþ double positive cells of the CD45þ
(high and low) population is shown. Patients were grouped as low percentage of bone marrow PC (0–10%) (n¼ 4), intermediate (10–30%) (n¼ 4), and
high (>30%) (n¼ 3). Each symbol represents one patient and P-value was calculated using Mann–Whitney Test.
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marrow monocytes resulted in TNFa, IL6, and CCL3
production (Fig. S2). Thus, both classical and non-classical
monocytes were present among the purified bone marrow
monocytes. However, taken together, the results indicate that
the CD16þCD14dim monocytes may produce inflammatory
cytokines that could support myeloma growth in response to
TLR8 ligands.Wefailed todetect IL10mRNAormRNAcoding
for any other anti-inflammatory cytokines in monocytes
enriched from the bone marrow and cultured with mCSF
(Fig. S5) or from monocytes sorted directly from the bone
marrow (data not shown).
Discussion
We found in this study that the proportion of non-classical,
CD16þCD14dim monocytes is small in patients with normal
Figure 3. Bone marrow monocytes stimulated with TLR8 ligands produce myeloma growth factors. (A) 100 000 sorted CD14high and CD16þCD14dim
bloodmonocytes were cultured with 100ng/mL LPS, 1mg/mL CL075 or medium alone for 12 h in 100mLmedium in a 96well plate. TNFawasmeasured
in the supernatant by ELISA. (B,C) CD16þCD14dim bone marrow monocytes from myeloma patients produce cytokines after stimulation with TLR8
agonist. Monocytes were immunomagnetically puriﬁed from bone marrow of myeloma patients as described. A total of 200,000 cells were stimulated
with 1mg/mL TLR8 agonist (CL075) or medium for 24 h before harvesting the supernatant, (B) TNFa secretion in the supernatant of monocytes from
three representative patients out of eight analyzed. The monocytes were enriched from bone marrow as described in the Materials and Methods and
stained with anti CD16 and anti CD14 after enrichment (patient 1: 9.3% CD16þCD14dim, patient 2: 10.3% CD16þCD14dim, patient 3: 13.8%
CD16þCD14dim). (C) CD16þCD14dim monocytes produce myeloma growth factors after TLR8 stimulation. (D) IL6 and CCL3 in the supernatant from
one representative patient out of eight analyzed. Cytokines were detected using Multiplex (27 plex BioRad). Figures shows mean and SEM of triplicate
wells from each patient analyzed (D).
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to low bone marrow levels of PC (i.e., approx. 2% PC), and
that the amount of these monocytes increases with tumor
load in myeloma bone marrow (Fig. 1D). In contrast, we did
not observe any significant change in the CD14high monocyte
population (Fig. 1D). The variation in monocyte levels seen
in patients with high tumor load could be because the
proportion of monocytes of the CD45þ population will drop
as the number of CD45þ PC increase. Alternatively, there
could be a disruption in hematopoiesis in patients with high
tumor loads [16, 17]. Patients with advanced disease and
high tumor load often present with anemia, leukopenia, and
thrombocytopenia of indicative of defective hematopoie-
sis [18]. At the late stage of the disease, the tumor is often not
dependent on growth factors or the bonemarrowmilieu [19]
and may therefore not require the presence of macrophages/
monocytes in the bonemarrow. There weremore of the non-
classical monocytes CD16þCD14dim in patients with
apoptotic myeloma cells. These could be stimulated with
TLR8 ligands implying that they are functional monocytes
and that they can produce cytokines in response to certain
stimuli that may promote myeloma growth. Indeed, we
found that supernatant from sorted non classical monocytes
were able to support the growth of the myeloma cell line
INA6 (Fig. S3b) suggesting that these cells could support the
growth of myeloma cells in patents.
The expansion of the non-classical monocytes could be
generated by several and non-mutually exclusive mechanisms.
Even in cases where there are well-established correlations
between non-classical monocytes and certain diseases, we do
not know directly why that is the case, although it has been
suggested that immune complexes or nucleic acids stimulate
non-classical monocytes to expand and produce inflammatory
cytokines and sterile inflammation.
It is proposed that sterile inflammation is one of the
mechanisms behind symptoms of multiple myeloma [2] and
this could lead to the expansion of the non-classical
monocytes after stimulation with TLR ligands. Thus, it
has been proposed that dying cancer cells could cause this
inflammation [2]. Indeed, is was shown in mouse models
that macrophage activation and sterile inflammation was
induced where DNA from apoptotic cells accumulated in
macrophages [14]. In line with this, we found an elevation of
TRAIL and Lymphotoxin concentrations in the bone
marrow of myeloma patients compared with controls in
another cohort of patients (unpublished results) indicating
that cell death and inflammation takes place. Thus, our data
could suggest that components from apoptotic cells were
responsible for stimulating the CD16þCD14dim population
in the myeloma patients. This is supported by the
observation that increased IL1Ra and MIP1a, which has
been associated with activation of CX3CR1 monocytes, were
raised in the bone marrow of myeloma patients compared
with healthy controls [20].
The relationship between the classical and non-classical
monocyte populations is not fully known, although in mice,
the CCR2þ, inflammatory monocytes and the CX3CR1
þ
patrolling monocytes are proposed to develop from different
precursors. It is, however, also possible that one population
could develop into the other during inflammatory con-
ditions [9]. In humans it has been reported that CD16 is up-
regulated in classical monocytes by TGFb1 production after
activation [21]. Myeloma cell produce high levels of TGFb1
(reviewed in [22], that potentially could up-regulate CD16
expression. Thus it is possible that CD14high monocytes
developed into the CD16þCD14 dim cells in the patients in
the presence of increased levels of PC. Alternatively,
CD16þCD14 dim cells could migrate to the bone marrow
from the circulation to areas of cell death.
Increased apoptosis in themyeloma cells from the patients
with high ratio of CD16þCD14dim cells, suggests the
presence of myeloma cell derived ligands such as cellular
DNA and RNA. However, the presence of such ligands has to
our knowledge not yet been identified in bone marrow
aspirates of myeloma patients. It is however possible that
apoptotic cells and DNA or RNA from apoptotic cells are
rapidly removed by macrophages adjacent to the dying
myeloma cell and will therefore not easily be detected.
In recent years, it has become evident that the micro
environment is very important not only in the oncogen-
esis of myeloma, but also in the clinical presentation and
response to treatment. Monocytes, macrophages, and
DCs are very important components of the myeloma
environment. Classical monocytes stimulated by myelo-
ma derived products and plasmacytoid DC [23] stimu-
lated with mitochondrial DNA released from dying
myeloma cells for example could support myeloma
growth. In addition, our observation that the non-
classical monocytes are present at a higher proportion in
patients with apoptotic myeloma cells, suggest that these
cells could be one of the cells types contributing to the
disease process. However, further experiments are
required to determine the mechanism behind the increase
of non-classical monocytes in multiple myeloma and how
they contribute to the disease.
Materials and Methods
Patients
Bone marrow cells were collected in Sodium Heparin
(Wockhardt, Wrexham, UK) from the pelvis of monoclonal
gammopathy of unknown significance (MGUS), newly
diagnosed and relapsing myeloma patients. The patients
were enrolled after informed consent and the study
was approved by the Regional Ethics Committee (REK
2011–2029). Percentage bone marrow PC and serum
A. M. Sponaas et al. Monocytes in multiple myeloma
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M-component were determined as part of standard
diagnostic procedures. Two patients out of the 33 analyzed
had moderately elevated CRP (>5 g/L), but without
indication of infection. Patients were divided in three
groups with similar age and sex distribution (Table 1). The
fraction of PC, median age and age range among the three
groups were: 0–10% PC [62 years, range from 44 to 72 (5
male, 4 female)] 10–30% PC (64.5 years, range from 50 to 84
(6 male, 6 female)],>30% PC [72 years, range from 53 to 86
(6 male, 6 female)]. The analysis was done on freshly
collected samples.
Reagents and antibodies
Anti-human CD66bFITC, CD3, CD19, CD14, CD163,
CD138, CD56, CD15 all PE conjugated, HLADRV450,
CD45V500, CD16APC-H7, CD14PE-Cy7, CD38PE-Cy7,
CD 206APC were obtained (BD Pharmingen, Stockholm,
Sweden). CD34PE, CD235aPE, CD11bPerCp-eFlour710
(eBioscience, San Diego, CA, USA), CD192APC, and
CX3CR1AlexaFlour647 were from BioLegend, San Diego,
CA, USA. Human FcReceptor binding inhibitor, 7AAD, and
Annexin V-Alexa647, were obtained from eBioscience, San
Diego, CA, USA, Sigma–Aldrich, (St. Louis, MO, USA), and
Molecular Probes, Eugene, OR, USA, respectively.
Flow Cytometry
Bone marrow cells were analyzed after RBC lysis in
hypotonic buffer (dH2O, NH4Cl, NaHCO3, EDTA). A total
of 0.5 million cells were stained with a cocktail of antibodies
against human CD66b, lineage (CD3, CD19, CD56, CD138,
CD34, and CD235a), CD45, HLADR, CD16, and CD14 for
30min on ice after 20min incubation with human Fc
Receptor binding inhibitor. Flow cytometry was performed
using LSR II (Becton Dickinson, Franklin Lakes, NJ, USA)
with FACS Diva software (Becton Dickinson). Samples were
analyzed with FlowJo 7.6 (TreeStar, Ashland, OR, USA). For
the monocyte population gates were set on live cells with
forward and side scatter and duplets were gated out. Lineage
and CD66bþ granulocytes were excluded and the CD14 and
CD16 were determined on the CD45þ, HLA-DRþ cells.
Myeloma cells were stained in a separate panel with CD3,
CD19, CD138, CD38, CD45, Annexin V, and 7AAD. Gates
were set on FSC and SSC and CD45þ cells were included
whilst lineage CD3þ and CD19þ cells were excluded. More
than 95% of the plasma cells in the patients expressed
CD45. % Annexin V and 7AAD double positive cells were
determined on all CD38þ CD138þ cells.
Cell sorting of monocytes from blood and bone
marrow
RBC lysis of peripheral blood was performed using a
hypotonic buffer before sorting of monocytes into
CD16þCD14dim and CD14high populations on FACS Aria
(Becton Dickinson) after staining with a cocktail of anti-
bodies against human CD66b, lineage (CD3, CD19, CD56,
CD138, CD34, and CD235a), CD45, HLADR, CD16, and
CD14 for 30min on ice. Before staining with antibodies the
cells were incubated for 20min with human FcReceptor
binding inhibitor. 7AAD (Sigma–Aldridge, St. Luis, MO,
USA) positive, dead cells and duplets were excluded. Sorting
gates were set as described in Figure 1. More than 95% purity
was achieved for both populations.
Enrichment of bone marrow monocytes by
immunomagnetic purification
Bonemarrowmonocytes were purified using a panmonocyte
isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany)
after density gradient centrifugation (Lymphoprep, Axis-
Shield, Oslo, Norway). This kit removes CD3, CD19 positive
cells. In addition we removed the CD66b and CD56 positive
cells adding biotinylated antibody. Figure S1 shows CD14
expression on the purified cells from a typical experiment.
90% or more of the cells expressed CD14. Flow cytometric
analysis showed that both CD16CD14high classical and
CD16þCD14dim non classical monocytes were after the
purification (data not shown).
Stimulation of monocytes
A total of 100,000 sorted blood monocytes or 200,000
immunomagnetically purified bone marrow monocytes
were cultured in RPMI 1640 (Sigma–Aldrich, Schnelldorf,
Germany) supplemented with L-glutamine (100mg/mL),
gentamycin (20mg/mL) and 20% heat-inactivated fetal calf
serum (FCS). The cells were stimulated with 100 ng/mL
lipopolysaccharide (LPS) (InVivogen, San Diego, CA, USA)
or 1mg/mL CL075 (InVivogen) for 12 h in 100mL in a 96
well flat bottomed tissue culture plate (Sigma-Aldridge,
Costar). Cytokines were measured in the supernatant by
Mulitplex or ELISA.
Table 1. Patients.
Group
(% plasma cells)
No
(total¼ 33)
Median age**
(range to-from) sex
0–10 9 62 (44–72) 5m, 4f
10–30 12* 64,5 (50–84) 6m, 6f
>30 12* 72 (53–86) 6m, 6f
*One patient withmoderately elevated CRP values of>5 g/L; but without
indication of bacterial or viral infection.
**Age at sampling.
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Cytokine assays
Cell culture supernatants or bone marrow plasma (stored at
808C) were analyzed for cytokines using Bioplex Precision
Human Cytokine Assay (27plex and 23plex assay, BioRAD,
Hercules, CA, USA) or ELISA (R&D Systems, Minneapolis,
MN, USA) following the suppliers protocol.
Statistical analysis
Tests were performed using Graph Pad Prism 5 software.
Correlations were determined using Spearmans Test.
Comparisons between groups were done with Mann–
Whitney. Significance was determined as P< 0.05.
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Fig. S1. Correlation between the ratios of CD16þCD14dim
cells/CD14high cells and percent apoptotic plasma cells in the
bone marrow of patients (n¼ 1).
Fig. S2. Purified monocytes were stained with antibodies
against CD16 and CD14 and analyzed on LSR II Flow
cytometer (BD Biosiences).
Fig. S3a. CD16-CD14high bone marrow monocytes from
myeloma patients produce cytokines after stimulation with
TLR4 agonis.
Fig. S4. Similar proportions of non classical monocytes in
the blood and bone marrow. Blood and bone marrow from
patients were stained with the same panel of antibodies as
described in Figure 1.
Fig. S5. Purified bone marrow cells were enriched as
described in Materials and Methods.
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